Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Observational, Long-term Follow-up Study for Subjects Who Previously Received Zamtocabtagene Autoleucel in a North American Miltenyi Biomedicine-Sponsored Clinical Study

NCT06116110 is registered in ClinicalTrials.gov with Miltenyi Biomedicine GmbH as lead sponsor.

NCT NCT06116110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06116110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Observational, Long-term Follow-up Study for Subjects Who Previously Received Zamtocabtagene Autoleucel in a North American Miltenyi Biomedicine-Sponsored Clinical Study
Lead sponsor
Miltenyi Biomedicine GmbH
Phase
Observational
Overall status
Recruiting
Start date
May 15, 2024
Completion date
December 1, 2041
Enrollment
150 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system lymphoma, high grade b-cell lymphoma, non hodgkin lymphoma, primary mediastinal b-cell lymphoma (pmbcl), refractory diffuse large b cell lymphoma (dlbcl), relapsed diffuse large b cell lymphoma